BioSyent (CVE:RX) Stock Crosses Above Fifty Day Moving Average – Time to Sell?

Shares of BioSyent Inc. (CVE:RX) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$12.47 and traded as high as C$12.60. BioSyent shares last traded at C$12.60, with a volume of 51,921 shares.

Analysts Set New Price Targets

Separately, Bloom Burton raised shares of BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research note on Friday, November 21st. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, BioSyent presently has an average rating of “Strong Buy”.

BioSyent Stock Down 1.2%

The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The stock has a market cap of C$141.91 million, a PE ratio of 16.84 and a beta of 0.55. The firm has a fifty day moving average of C$12.47 and a 200 day moving average of C$11.81.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.